Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies

Autor:	László Czirják, Andrew L. Taylor, Roberto Caporali, Lingli Dong, Gustavo Casado, Boulos Haraoui, Peter Button, Yves Luder
Rok vydání:	2019
Předmět:	medicine.medical_specialty lcsh:Diseases of the musculoskeletal system Combination therapy ACT-UP chemistry.chemical_compound Tocilizumab Rheumatology Quality of life Prednisone Internal medicine medicine Immunology and Allergy Rheumatoid arthritis Adverse effect Original Research business.industry medicine.disease Discontinuation Biologic factors chemistry lcsh:RC925-935 business medicine.drug
Zdroj:	Rheumatology and Therapy Rheumatology and Therapy, Vol 6, Iss 2, Pp 231-243 (2019)
ISSN:	2198-6584 2198-6576
DOI:	10.1007/s40744-019-0150-x
Popis:	Introduction The objective of this study was to observe the patterns of usage, efficacy, and safety of tocilizumab (TCZ) in clinical practice in patients with rheumatoid arthritis. Methods Data on the real-world usage, efficacy, and safety of TCZ were collected from patients during routine follow-up visits conducted over a 6-month period. Patients were grouped by previous exposure to biologic therapies (biologic exposed vs. biologic naive). Results Of 1912 patients enrolled from 16 countries, 639 (33.4%) received TCZ monotherapy and 1273 (66.6%) received TCZ combination therapy. At baseline, 1073 patients (56.1%) were biologic naive and 839 (43.9%) were biologic exposed. At 6 months, 1504 patients (78.7%) continued to receive TCZ treatment, with no descriptive differences in retention rates between biologic-exposed and biologic-naive patients and between patients receiving TCZ monotherapy or combination therapy. Dose and use of methotrexate and prednisone were reduced at 6 months. Efficacy at 6 months, including patient-reported outcomes, was demonstrated in both biologic-naive and biologic-exposed groups. Adverse events (AEs) occurred in 817 patients [42.7%; incidence rate: 179 events per 100 patient-years (PY)], and serious AEs (SAEs) occurred in 118 patients (6.2%; 17 events per 100 PY), with comparable rates of AEs and SAEs between subgroups. Conclusion In routine clinical practice, TCZ discontinuation rates were low and unaffected by prior use of biologics. Effectiveness was similar between groups, and no new safety signals were identified. Funding F. Hoffmann-La Roche. Electronic supplementary material The online version of this article (10.1007/s40744-019-0150-x) contains supplementary material, which is available to authorized users.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b349149c619d12b4cdb9b54bd52f4a5 https://doi.org/10.1007/s40744-019-0150-x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.